Hong Kong Stock Announcement Nuggets | Net profit attributable to the mid-term parent company holders of Yao Ming Kangde was about $11.08 billion, up 33.7% year-on-year

[Important matters]

Changfei Optical Fiber & Cable (06869) subsidiary plans to invest 170 million yuan to participate in the Changfei Smart Fund

Zhonglian Development Holdings (00264) signs procurement contract for prefabricated artificial intelligence data center modules

Keji Pharmaceutical-B (02171): CT0596 has received IND approval from the National Drug Administration for the treatment of relapsed/refractory multiple myeloma (R/R MM) patients

Corning Jerry Pharmaceutical-B (09966) signs a license agreement with PATHOS AI for JSKN016

China Biopharmaceutical (01177): TQB2102 “HER2 Dual Antibody ADC” was included in the CDE list of breakthrough therapeutics for the third time

Fosun Pharmaceutical (02196): The drug registration application for compound polyethylene glycol (3350) electrolyte dispersion was approved by the State Drug Administration

Fosun Pharmaceuticals (02196): Empagliflozin metformin extended-release tablets (III) received registration approval

CSPC Group (01093): Phase IB/II clinical trial of SYS 6090 injection for colorectal cancer was officially launched at the first research center in China

Shisi Pharmaceutical Group (02005) bid for a total of 13 varieties and 16 product specifications, all of which are to be selected for centralized drug procurement throughout the country

Fussen Pharmaceutical (01652): Four products plan to win the bid for centralized procurement of drugs nationwide

Shanghai Pharmaceutical (02607): Omeprazole sodium bicarbonate dry suspension (I) approved for production

Yinnuo Pharmaceutical-B (02591): Two production sites commissioned to obtain PIC/s GMP certificates for esupaglutide α injections

Corning Jerry Pharmaceutical-B (09966): JSKN033 received approval from CDE to conduct a phase III clinical study to treat cervical cancer

Maike Pharmaceutical-B (02335): MT200605 phase II clinical trial for acute ischemic stroke (AIS) reached the main end

[Bonds and notes]

GAC Group (02238) plans to apply for registration to issue debt financing instruments with a total principal amount not exceeding 15 billion yuan

[Buy/increase or decrease holdings]

Huaqin Technology (03296) spent 60.31 million yuan to buy back 808,000 A shares on August 3

Midea Group (00300) spent about 507.621 million yuan to buy back 588,300 A shares on August 3

Xiaomi Group-W (01810) spent HK$49,958 million to buy back 1.788 million shares on August 3

Lanqi Technology (06809) spent 39.21 million yuan to buy back 205,000 A-shares on August 3

Hengrui Pharmaceutical (01276) spent 337.36 million yuan to buy back 637,000 A-shares on August 3

On August 3, Sanhuan Group (06951) spent 193.14 million yuan to buy back 172,700 A-shares

[Business performance]

Yao Ming Kangde (02359) announced interim results. Net profit attributable to parent company holders was about 11.08 billion yuan, a year-on-year increase of 33.7%, with a year-on-year increase of 5.1 yuan for every 10 shares

Accelerating global layout+AI research and development of dual-wheel drive celadon games (06633), net profit for the first half of the year is expected to increase by 320%-361% year-on-year

Xiaopeng Group-W (09868) delivered about 38,000 new cars in July, an increase of 4% year-on-year

Cyrus (09927) produced about 27,600 vehicles in July and sold about 26,700 vehicles

SF Express Tongcheng (09699) Fa Yingxi expects profit attributable to shareholders to increase by no less than 120% year-on-year in the first half of the year

China Cinda (01359) issued a profit warning. Net profit attributable to shareholders is expected to drop by about 60% to 70% year-on-year in the medium term